Trial Profile

Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ferric carboxymaltose (Primary)
Indications Heart failure; Left ventricular dysfunction
Focus Therapeutic Use
Acronyms IRON-CRT

Most Recent Events

18 Mar 2022 Results published in the European Journal of Heart Failure
29 Jun 2021 Primary endpoint (Change in left ventricular ejection fraction from baseline) has been met, as per results published in the European Heart Journal.
29 Jun 2021 Status changed from recruiting to discontinued due to poor enrolment in one of the centres (no patients were enrolled at Jessa Hospital as this site was activated just before the COVID-19 pandemic) as per results published in the European Heart Journal.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com